Legislation seeks greater EC awareness
This article was originally published in The Tan Sheet
Executive Summary
Sen. Patty Murray and Rep. Louise Slaughter introduce the Emergency Contraception Education Act of 2010, authorizing a public education campaign through the Centers for Disease Control and Prevention to increase EC awareness among women and health care providers. "We must educate women about their options so they can make well-informed choices about their reproductive health," said Slaughter, D-N.Y., adding studies show one-third of women are unaware of EC drugs, such as the nonprescription levonorgestrel products Plan B One-Step and Next Choice. Murray, D-Wash., and Slaughter introduced 1S. 3504 and H.R. 5561 June 17, and have offered similar legislation in previous sessions of Congress (2"The Tan Sheet" Oct. 1, 2007, In Brief)
You may also be interested in...
Senators introduce Plan B awareness bill
Sens. Hillary Clinton, D-N.Y. and Patty Murray, D-Wash., introduced legislation Sept. 27 to raise awareness about the availability of Plan B emergency contraception, which FDA approved for OTC use last year for individuals ages 18 and over (1"The Tan Sheet" Aug. 28, 2006, p. 3). Rep. Louise Slaughter, D-N.Y. introduced companion legislation, H.R. 3372, in August. The proposed program would direct the Department of Health and Human Services to establish a public education program through the Centers for Disease Control and Prevention designed to provide information to the public about emergency contraception. According to statistics cited by the lawmakers, one-third of U.S. women of reproductive age are unaware of Plan B's availability, and implementing an educational program will help reduce unintended pregnancies and decrease the number of abortions...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.